[Raynaud's phenomenon and finger necrosis after treatment of ovarian seminoma with bleomycin, vinblastine and 5-fluorouracil].
Bleomycin is sometimes at the origin of a Raynaud's phenomenon (RP). From the literature, there does not seem to exist a dose-dependent relationship. The phenomenon occurs early or late and often is resistant to various medications. The possible physiopathological mechanisms are: direct vascular toxicity, hypersensitivity vascularization, alteration of platelets activity, alteration of Willebrand's factor, and as predisposing factors: association to periwinkle alkaloids or hypomagnesemia.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D004407:Dysgerminoma / Q000188:drug therapy*; D005260:Female; D005385:Fingers / Q000473:pathology*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D009336:Necrosis; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011928:Raynaud Disease / Q000139:chemically induced*; D014747:Vinblastine / Q000627:therapeutic use
D001761:Bleomycin; D014747:Vinblastine; D005472:Fluorouracil
Phénomène de Raynaud et nécrose digitale après traitement d'un séminome ovarien par bléomycine, vinblastine et 5-fluoro-uracile.